Articles |
From the Hatter Institute for Cardiovascular Studies, Department of Cardiology (H.E.M., C.D., J.M., J.D., J.R.M.), and the Rayne Institute, Division of Cardiovascular Genetics, Department of Medicine (F.B., S.H.), University College London Medical School; the Department of Vascular Studies, Great Ormond Street Children's Hospital, London (P.C.); the Department of Chemical Pathology, The Royal Free Hospital, Hampstead, London (O.M.N., D.P.M., I.A.J., A.W.); the Army Training Regiment, Bassingbourn, Hertfordshire (M.J.); and the Royal Army Medical College, Millbank, London (M.W.), UK.
Correspondence to Dr Hugh Montgomery, University College London Medical School, The Hatter Institute Department of Academic and Clinical Cardiology, University College Hospital, Grafton Way, London WC1E 6DB, UK.
| Abstract |
|---|
|
|
|---|
Key Words: exercise training fibrinogen G/A polymorphism
| Introduction |
|---|
|
|
|---|
Lack of physical fitness is an independent risk factor for cardiovascular mortality,17 and a dose-response relationship18 exists between regular physical exercise19 20 and reduced cardiovascular risk.21 22 23 This relationship applies to primary ischemic heart, cerebrovascular,24 25 and peripheral vascular disease,26 as well as to secondary prevention.27 28 Some of the benefit of regular exercise is lost, however, if the exercise undertaken is very intense.29 Further, an episode of very intense exercise may acutely elevate the risk of a subsequent myocardial infarction,30 and this risk is greater in those with a sedentary lifestyle.31
The effects of exercise on cardiovascular risk may be partly mediated through alterations in plasma fibrinogen concentration.32 However, the few studies of the effects of chronic exercise training33 34 or acute intense exercise35 36 on plasma fibrinogen have examined only small numbers of individuals (often <12).
Studies of the effect of acute exercise on a background of chronic training are scarce and conflicting,37 38 39 and the time course of the acute response remains ill defined. Further studies have been advocated.34 Fibrinogen levels increase with advancing age40 and are related to other cardiovascular risk factors, being higher in diabetics and smokers.12 16 41 42 43 They are also influenced by genetic determinants.44 45 The fibrinogen molecule comprises two subunits, each composed of three polypeptide chains (Aa, Bß, and y) encoded by a different gene (FGA, FGB, and FGG, respectively) clustered on chromosome 4. Synthesis of the Bß chain is the rate-limiting step in the synthesis of fibrinogen46 and is responsive to cytokines such as IL6.47 Environmental factors may thus interact with genetic factors, such as polymorphisms of the fibrinogen gene locus, in the control of fibrinogen levels.48 Several such polymorphisms have been identified that are associated with differences in fibrinogen levels at baseline.40 44 45 49 Of these, the G-A substitution in the 5' flanking promoter sequence of the ß-fibrinogen gene has been consistently associated with differences in fibrinogen levels,40 49 50 and recent data suggest that it interacts strongly with factors such as gender, and hormonal and environmental factors.51 This being so, it might be that the acute-phase response of fibrinogen to physiological stress may also be partly determined by this polymorphism.
We sought to clarify these issues by investigating the fibrinogen response to chronic exercise training and to acute severe exercise in fit individuals and the role of the G/A polymorphism of the fibrinogen gene in regulating these responses.
| Methods |
|---|
|
|
|---|
|
Fibrinogen Assay
Venous whole blood was collected (9 mL
blood+1 mL 3.8%
trisodium citrate), centrifuged (300g for 15
minutes), and platelet-poor plasma derived. Assay of plasma
fibrinogen was performed by the Clauss (nephelometric) method adapted
for an ACL 300 (Research) instrument (IL Laboratories). Normal
laboratory range was 200 to 350 mg/dL.
Fibrinogen Genotype
Venous blood (5 mL) was taken into EDTA
sample tubes, stored at
-20°C, and DNA extracted by the "salting out"
method.51 Genotype at the G-445-A position was
determined by polymerase chain reaction using
oligonucleotides and conditions as previously
described.51 DNA was digested with Hae
III, and fragments were separated by electrophoresis on a 3%
agarose gel.49
Statistical Analysis
Data were expressed as F1, F2, and FCF.
Analysis was
performed using the SPSS-PC package. No data transformation was
required, as fibrinogen levels were normally distributed within the
sample. Data for each of the groups A through E were analyzed
separately. F1 and F2 within groups were compared using paired
t tests, and differences in FCF between groups by
one-way ANOVA and Fisher's exact test. To examine the effect of
genotype on FCF and plasma fibrinogen levels F1 and F2, data
were adjusted by multiple linear regression analysis for the
effects of age, BMI (kg/m2), and reported smoking habit
(coded as 0=nonsmoker, 1=smoker, 2=ex-smoker). Effects of
genotype were estimated on the adjusted data by ANOVA. The
correlation between fibrinogen levels at F1 and F2 was estimated using
the Spearman correlation coefficient. Values of P<.05 were
taken to be statistically significant.
| Results |
|---|
|
|
|---|
Fibrinogen concentrations (see the Table
and Fig 1
) rose
significantly from baseline values on days 1 through 3 after the
intensive physical effort of the 2-day ME (27.2%, P<.001;
37.1%, P<.001; 19.9%, P=.04, respectively) and
were lower at day 5 (11.9%, P=.04). There was no
significant change in fibrinogen concentration at 12 hours after ME and
at 4 days after ME. The peak percentage rise in fibrinogen
concentration on day 2 was significantly greater than at any other time
point (P<.05 for all comparisons) (see the Table
and Fig 1
).
|
Influence of G/A Polymorphism
Fibrinogen G/A genotype was
determined in 224 subjects at
entry and was available in 149 of the 156 with paired (pretraining and
posttraining) fibrinogen levels. The relative frequency of the A
allele (0.192) was not significantly different from that reported
for individuals in the United Kingdom,49 51 and
genotype distribution was consistent with
Hardy-Weinberg equilibrium.
The relationship between genotype and
fibrinogen levels F1 and
F2 was examined by ANOVA. Fibrinogen levels were slightly higher (but
not statistically significant) in the combined group of men with one or
more A alleles compared with those homozygous for the G allele,
being 4.2% and 4.5% higher for F1 and F2, respectively (Table
).
Plasma fibrinogen concentration rose maximally in groups B and C (days
1 and 2), after which the response began to decline. Any association
between G/A polymorphism and the acute-phase response to
exercise would therefore be expected to be most evident on these days.
There was a significant rise in fibrinogen concentration overall
(P<.001), but the degree of rise was genotype
dependent (Fig 2
), being (mean±SE) 26.7±5.4%,
36.5±11.0%, and 89.2±30.7% for GG, GA, and AA genotypes,
respectively, P=.01; and 26.7±5.4% versus
50.9±12.9% for
GG versus those with one or more A allele, P<.05. The
effect of the A allele remains if the data for the group showing
maximal rise (day 2, group C) are examined alone (FCF, 29.5%
[n=24],
37.1% [n=6], and 108.9% [n=2];
P=.016). However, the
effect is weakened by the inclusion of a group in whom the acute
fibrinogen response is already declining (ie, days 1, 2, and 3) in
which rise in fibrinogen was 25.8±4.6% for those of the GG
genotype compared with 35.1±9.1% (P=.14).
|
| Discussion |
|---|
|
|
|---|
Cross-sectional and epidemiological studies support the existence of a reduction in plasma fibrinogen concentration with chronic exercise training. Cardiorespiratory fitness52 and amount of exercise53 54 55 56 correlate inversely with fibrinogen levels, which are thus reduced in athletes.57 However, the effects of training are not consistent,38 and previous prospective studies, hampered by small, mixed cohorts and diverse training protocols, have produced variable results in the young.33 34 Even so, fibrinogen levels may fall with training in patients with cardiovascular disease58 59 and have decreased by more than 15% in young males with 9 weeks of training.60
We have demonstrated (Fig 1
and Table
) that
fibrinogen levels are
significantly (11.9%) reduced after 10 weeks of training if 5 days
without severe exertion intervene, an effect in keeping with a
beneficial effect of chronic training on fibrinogen levels.
Fibrinogen is a hepatically derived acute-phase
protein,47 61 62 63 whose
synthesis is responsive to
cytokines.47 49 Whereas regular exercise may
reduce fibrinogen levels, severe exercise might paradoxically cause an
acute-phase rise,35 36 although this theory is
debated.38 However, we have confirmed a prolonged rise in
response to acute severe exercise (Fig 1
and the
Table
). Fibrinogen
levels at day 5 probably more closely approximate the new "basal
levels" induced by chronic training. Within 12 hours of the
completion of a 2-day ME, fibrinogen levels are already 14.5% higher
than those at 5 days, suggesting that the acute response has already
begun. The duration of the rise (at least 3 days) may be related to
continued fibrinogen production or to its long plasma
half-life (4.5 to 6.5 days).33 Interestingly, the time
course of this response is similar to that seen after the
physiological stress of myocardial
infarction.63
Indices of hydration (such as hematocrit) were not documented. However, all troops had free access to fluids throughout both ME and the follow-up period. Further, any minor fluid deficits would have been most significant immediately upon return from ME and would have rapidly corrected during early follow-up. Nonetheless, fibrinogen levels continued to rise long after this. Thus the effects of fluid balance would only have acted to reduce the perceived rise.
Body composition was not assessed before and after training (although skeletal muscle mass may have been expected to rise and fat content perhaps to fall). However, this parameter is unlikely to have influenced the acute-phase rise itself.
The effects of previous training on the response to acute exercise have been disputed. Keber et al37 suggested that an acute early rise in fibrinogen concentration occurred in response to acute exercise at all levels of fitness, although Dufaux et al39 suggest that a delayed rise after prolonged severe exercise may be abolished by prior training. Our data suggest that any such "protective" effect is incomplete. Differences in study design (differing background fitness and acute exercise burden, study of early [minutes] or delayed [days] fibrinogen responses) probably account for these differing findings.
Changes in fibrinogen concentration may mediate some of the beneficial effects of exercise observed on cardiovascular risk. Fibrinogen is a cardiovascular risk factor64 perhaps as important as serum cholesterol, BMI, and BP.4 8 10 11 64 Regular physical exercise reduces cardiovascular morbidity and mortality17 19 20 22 23 in a dose-dependent fashion,18 29 an effect hard to explain by the effects on other factors such as lipid profile65 or BP.66 Just as chronic exercise lowers both fibrinogen concentration and cardiovascular risk, acute severe exercise may be procoagulant36 and raise cardiovascular risk.30 31 Some of the benefits of regular exercise are lost with very high exercise energy expenditures per week.29 As well as demonstrating a strong interaction between an environmental stimulus and fibrinogen gene expression, we have shown that this response may be strongly influenced by polymorphisms within the gene itself.
As expected from previous studies of the association between the
G-453-A ß-fibrinogen gene polymorphism and fibrinogen
levels,49 51 those with one or more A alleles had
modestly (4.5%) higher levels at entry. A clear pattern of change in
fibrinogen concentration with respect to baseline values was seen over
the 5 days following a major episode of physical exercise (ME) (Fig
1
).
In groups B and C, who were examined on days 1 and 2 after ME,
fibrinogen levels were rising to a peak as part of an acute response.
Fibrinogen levels were 27.2% and 37.1% higher than baseline on these
2 days. Among this acute response group, fibrinogen levels rose by
26.7% for those homozygote for the G allele and by almost twice as
much (50.9%) in those with one or more A alleles. Although the
group was small, the differences were statistically significant, and
the size of the effect is sufficient to be of biological significance.
In particular, the three men homozygous for the A allele
(representing 4% of the population based on the observed
allele frequencies) had fibrinogen levels that had risen by more
than 89% compared with their "untrained" levels and that were
among the highest levels in the whole sample.
These finding are in accord with cross-sectional data showing an interaction between fibrinogen genotype and smoking (an inducer of the acute-phase response) in determining fibrinogen levels50 67 and support an association of the A allele with greater fibrinogen level "responsiveness."68
The molecular mechanisms underlying this association are unclear. Transcription of the ß-fibrinogen gene is the rate-limiting step in hepatocyte fibrinogen production,46 49 and the G/A polymorphism may influence the binding of transcription factors. The G/A change at position 453 is also a marker for a T/C change at position 148 of the promoter, with A and C always occurring together and G and T always occurring together in Caucasians.69 This T/C change is located within a sequence of DNA that confers responsiveness to IL6 in in vitro assays.47 This behavior raises the possibility that either the C-148 sequence alone or the A-453 plus C-148 sequence in combination have a direct effect on the control of ß-fibrinogen synthesis in response to IL6-mediated stimuli such as smoking, inflammation, and tissue damage.
The homogeneity of the study population and environment limited the confounding effects of age,34 38 40 44 57 sex,44 51 hypertension,70 diet,16 smoking history,12 16 41 42 43 71 72 background fitness, exercise nature and intensity,59 73 and season of study74 on fibrinogen levels. Initial fibrinogen concentrations were thus similar in all groups. However, our study does have limitations: it is of cohort design, and logistics of military training prevented us from repeated study of individuals over multiple time points. We were unable to plot the true baseline fibrinogen levels after chronic training (recruits disband 6 days after ME) or assess the early phases of the acute-phase response. Fibrinogen concentrations were >14% higher when first measured after ME than those at day 5 (perhaps more representative of the new posttraining baseline), suggesting that levels had already risen. Indeed, the acute response may comprise an early (within hours)36 and delayed (over days)39 component. Fibrinogen concentrations were still falling rapidly from days 2 through 5 and may well have continued doing so for some time afterward. We have assumed that the fall in fibrinogen concentration at day 5 compared with that at intake represents an effect of chronic training. We were unable to enforce complete rest over the days following ME, although no specific physical training sessions or major exercises were held during this period.
Finally, the number of patients in the genotype analysis is small, especially in the A/A group. Nonetheless, comparisons are statistically significant. A gradient of increasing acute fibrinogen response is seen across the GG, GA, and AA genotypes, respectively, consistent with a different effect attributable to each allele.
In conclusion, our data demonstrate a rise in plasma fibrinogen in response to severe exertion and show that this rise occurs even in physically fit individuals in whom chronic exercise training may have led to a background reduction in plasma fibrinogen concentration. Given that a fall in fibrinogen concentration of just 0.1 g/L might correspond to a cardiovascular risk reduction of 15%,60 at least part of the cardiovascular benefit of regular exercise (and detrimental effects of chronic and acute intensive exercise) may derive from an associated change in fibrinogen levels. The intensity of the response may be influenced strongly by polymorphisms within the gene itself, raising the possibility that individuals homozygous for the A allele may be at particular risk of a thrombotic event after an acute-phase stimulus. Once identified, such individuals may benefit from risk factor reduction.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received September 11, 1995; accepted November 10, 1995.
| References |
|---|
|
|
|---|
2. Duguid JB. Thrombosis as a factor in the pathogenesis of aortic atherosclerosis. J Pathol Bacteriol. 1948;58:207-212.
3. Velican D, Velican C. Study of fibrous plaques occurring in the coronary arteries of children. Atherosclerosis. 1979;33:201-215. [Medline] [Order article via Infotrieve]
4.
Di Minno G, Mancini M. Measuring plasma
fibrinogen to predict stroke and myocardial infarction.
Arteriosclerosis. 1990;10:1-7.
5. Watanabe K, Tanaka K. Influence of fibrin, fibrinogen and fibrinogen degradation products on cultured endothelial cells. Atherosclerosis. 1983;48:57-70. [Medline] [Order article via Infotrieve]
6. Ishida T, Tanaka K. Effects of fibrin and fibrinogen-degradation products on the growth of rabbit aortic smooth muscle cells in culture. Atherosclerosis. 1982;44:161-174. [Medline] [Order article via Infotrieve]
7. Shah P, Chander R, Daly K. Plasma fibrinogen level and other risk factor profile: association with coronary artery disease. Br Heart J. 1995;71:25. Abstract.
8. Meade TW, North WR, Chakrabarti R, Stirling Y, Haines AP, Thompson SG, Brozovic M. Hemostatic function and cardiovascular death: early results of the Northwick Park Heart study. Lancet. 1980;1:1050-1054. [Medline] [Order article via Infotrieve]
9. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Hemostatic function and ischemic heart disease: principal results of the Northwick Park Heart study. Lancet. 1986;2:533-537. [Medline] [Order article via Infotrieve]
10.
Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O'Brien
JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white
blood cell count are major risk factors for ischemic heart
disease. Circulation. 1991;83:836-844.
11. Stone MC, Thorp JM. Plasma fibrinogen: a major coronary risk factor. J R Coll Gen Pract. 1985;35:565-569. [Medline] [Order article via Infotrieve]
12. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505. [Abstract]
13.
Kannel WB, Wolf PA, Catelli WP, D'Agostino RB.
Fibrinogen and risk of cardiovascular disease: the
Framingham study. JAMA. 1987;258:1183-1186.
14. Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentrations as risk factors for transient ischemic attacks and minor ischemic strokes. BMJ. 1991;303:605-609.
15. Resch K, Ernst E, Matrai A, Paulsen H. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med. 1992;117:371-375.
16. Ernst E. Plasma fibrinogen: an independent cardiovascular risk factor. J Intern Med. 1990;227:365-372. [Medline] [Order article via Infotrieve]
17.
Slattery ML, Jacobs DR. Physical fitness and
cardiovascular disease mortality. Am J
Epidemiol. 1988;127:571-580.
18.
Berlin JA, Colditz GA. A
meta-analysis of physical activity in the prevention of
coronary heart disease. Am J Epidemiol. 1990;132:612-628.
19.
Slattery ML, Jacobs DR, Nichaman MZ. Leisure
time physical activity and coronary heart disease: the US
Railroad study. Circulation. 1989;79:304-311.
20. Morris JN, Everitt MG, Pollard R, Chave SPW. Vigorous exercise in leisure-time: protection against coronary heart disease. Lancet. 1980;2:1207.[Medline] [Order article via Infotrieve]
21.
Simonsick EM, Lafferty ME, Phillips CL, Mendes de Leon
CF, Kasl SV, Seeman TE, Fillenbaum G, Hebert P, Lemke JH. Risk
due to inactivity in physically capable older adults. Am
J Public Health. 1993;83:1443-1450.
22. Morris JN, Heady JA, Raffle PAB, Roberts CG, Parks JW. Coronary heart disease and physical activity at work. Lancet. 1953;2:1111-1120.
23. Fox SM III, Naughton JP, Gorman PA. Physical activity and cardiovascular health, I: potential for prevention of coronary heart disease and possible mechanisms. Mod Concepts Cardiovasc Dis. 1972;41:17-20. [Medline] [Order article via Infotrieve]
24. Shinton R, Sagar G. Lifelong exercise and stroke. BMJ. 1993;307:231-234.
25. Wannamethee G, Shaper AG. Physical activity and stroke in British middle aged men. BMJ. 1992;304:597-601.
26.
Housley E, Leng GC, Donnan PT, Fowkes FGR.
Physical activity and risk of peripheral
arterial disease in the general population: Edinburgh
Artery Study. J Epidemiol Community
Health. 1993;47:475-480.
27. May GS, Eberlein KT, Furbery CD, Passamani ER, De Mets DL. Secondary prevention after myocardial infarction: a review of long-term trials. Prog Cardiovasc Dis. 1982;23:331-352.
28.
O'Connor GT, Buring JE, Yusuf S, Goldhaber SZ,
Olmstead EM, Paffenbarger RS, Hennekens CH. An overview of
randomized trials of rehabilitation with exercise after myocardial
infarction. Circulation. 1989;80:234-244.
29. Paffenbarger RS, Hyde RT, Wing AL, Hsieh C. Physical activity, all-cause mortality, and longevity of college alumni. N Engl J Med. 1986;314:605-613. [Abstract]
30.
Willich SN, Lewis M, Lowel H, Arntz H-R, Schubert F,
Schroder R. Physical exertion as a trigger of acute myocardial
infarction. N Engl J Med. 1993;329:1684-1690.
31. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Mullers JE. Triggering of acute myocardial infarction by heavy physical exertion: protection against triggering by regular exertion. N Engl J Med. 1993;329:1678-1683.
32.
Ernst E. Regular exercise reduces fibrinogen
levels: a review of longitudinal studies. Br J Sports
Med. 1993;27:175-176.
33. Fendler K, Lissak K, Romhanyi M, Osz E, Szucs R, Kovacs GL. Adaptive processes in child and adolescent swimmers: blood coagulation and viscosity. Acta PhysiolAcad Sci Hung. 1977;49:17-26.
34.
Stratton JR, Chandler WL, Schwartz RS, Cerqueira MD,
Levy WC, Kahn SE, Larson VG, Cain KC, Beard JC, Abrass IB.
Effects of physical conditioning on fibrinolytic variables and
fibrinogen in young and old healthy adults.
Circulation. 1991;83:1692-1697.
35. Arai M, Yorifuji H, Ikematsu S, Nagasawa H, Fujimaki M, Fukutake K, Katsumura T, Ishii T, Iwane H. Influences of strenuous exercise (triathlon) on blood coagulation and fibrinolytic system. Thromb Res. 1990;57:465-471. [Medline] [Order article via Infotrieve]
36. Hansen J, Wilsgard L, Olsen JO, Osterud B. Formation and persistence of procoagulant and fibrinolytic activities in circulation after strenuous physical exercise. Thromb Haemost. 1990;64:385-389. [Medline] [Order article via Infotrieve]
37. Keber D, Stegnar M, Keber I, Accetto B. Influence of moderate and strenuous daily physical activity on fibrinolytic activity of blood: possibility of plasminogen activator stores depletion. Thromb Haemost. 1979;41:745-755. [Medline] [Order article via Infotrieve]
38.
Moxley RT, Brakman P, Astrup T. Resting levels
of fibrinolysis in blood in inactive and exercising
men. J Appl Physiol. 1970;28:549-552.
39. Dufaux B, Order U, Hollman W. Can exercise induce an effective fibrinolysis? Thromb Res. 1984;36:37-43. [Medline] [Order article via Infotrieve]
40.
Scarabin P-Y, Bara L, Ricard S, Poirier O, Cambou JP,
Arveiler D, Luc G, Evans AE, Samama MM, Cambien F. Genetic
variation at the ß-fibrinogen locus in relation to plasma
fibrinogen concentrations and risk of myocardial infarction: the ECTIM
study. Arterioscler Thromb. 1993;13:886-891.
41. Wilkes HC, Kelleher C, Meade TW. Smoking and plasma fibrinogen. Lancet. 1988;1:307-308. [Medline] [Order article via Infotrieve]
42.
Yarnell JW, Sweetnam PM, Rogers S, Elwood PC, Bainton
D, Baker IA, Eastham R, O'Brien JR, Etherington MD. Some
long-term effects of smoking on the hemostatic system: a report
from the Caerphilly and Speedwell Collaborative Surveys.
J Clin Pathol. 1987;40:909-913.
43. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham study. Am Heart J. 1987;113:1006-1010. [Medline] [Order article via Infotrieve]
44. Heinrich J, Funke H, Rust S, Schulte H, Schonfeld R, Kohler E, Assmann G. Impact of polymorphisms in the alpha- and beta-fibrinogen gene on plasma fibrinogen concentrations of coronary heart disease patients. Thromb Res. 1995;77:209-215. [Medline] [Order article via Infotrieve]
45. Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW. Role of genetic variation at fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet. 1987;1:1452-1455. [Medline] [Order article via Infotrieve]
46.
Roy SN, Mukhopadhyay G, Redman CM. Regulation of
fibrinogen assembly: transfection of Hep G2 cells with B beta cDNA
specifically enhances synthesis of the three component chains of
fibrinogen. J Biol Chem. 1990;265:6389-6393.
47.
Dalmon J, Laurent M, Courtois G. The human beta
fibrinogen promotor contains a hepatocyte nuclear factor
1dependent interleukin-6responsive element. Mol Cell
Biol. 1993;13:1183-1193.
48. Reed T, Tracy RP, Fabsitz RR. Minimal genetic influences on plasma fibrinogen level in adult males in the NHLBI Twin Study. Clin Genet. 1994;45:71-77. [Medline] [Order article via Infotrieve]
49. Thomas AE, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, Meade TW, Humphries SE. Variation in the promotor region of the ß fibrinogen gene is associated with plasma fibrinogen levels in smokers and nonsmokers. Thromb Haemost. 1991;65:487-490. [Medline] [Order article via Infotrieve]
50. Green F, Hamsten A, Blomback M, Humphries S. The role of beta-fibrinogen genotype in determining plasma fibrinogen levels in survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost. 1993;70:915-920. [Medline] [Order article via Infotrieve]
51.
Humphries SE, Ye S, Talmud P, Bara L, Wilhelmsen L,
Tiret L. European Atherosclerosis Research
Study: genotype at the fibrinogen locus (G455-A beta-gene)
is associated with differences in plasma fibrinogen levels in young men
and women from different regions in Europe: evidence for
gender-genotype-environment interaction.
Arterioscler Thromb Vasc Biol. 1995;15:96-104.
52. Rankinen T, Rauramaa R, Vaisanen S, Penttila IM, Uusitupa M. Relation of habitual diet and cardiorespiratory fitness to blood coagulation and fibrinolytic factors. Thromb Haemost.. 1994;71:180-183. [Medline] [Order article via Infotrieve]
53. Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. J Clin Epidemiol. 1990;9:913-919.
54. Rosengren A, Wilhelmsen L, Welin L, Tsipogianni A, Teger-Nilsson AC, Wedel H. Social influences and cardiovascular risk factors as determinants of plasma fibrinogen concentration in a general population sample of middle aged man. BMJ. 1990;300:634-638.
55.
Morris JN, Clayton DG, Everitt MG, Semmence AM, Burgess
EH. Exercise in leisure time: coronary attack and death
rate. Br Heart J. 1990;63:325-334.
56. Rankinen T, Rauramaa R, Vaisanen S, Penttila I, Saarikoski S, Tuomilehto J, Nissinen A. Inverse relationship between physical activity and plasma fibrinogen in postmenopausal women. Atherosclerosis. 1993;102:181-186. [Medline] [Order article via Infotrieve]
57. Speiser W, Langer W, Pschaick A, Selmayr E, Ibe B, Nowacki PE, Muller-Berghaus G. Increased blood fibrinolytic activity after physical exercise: comparative study in individuals with different sporting activities and in patients after myocardial infarction taking part in a rehabilitation sports program. Thromb Res. 1988;51:543-555. [Medline] [Order article via Infotrieve]
58.
Ernst EEW, Matrai A. Intermittent claudication,
exercise, and blood rheology. Circulation. 1987;76:1110-1114.
59.
Wosornu D, Allardyce W, Ballantyne D, Tansey P.
Influence of power and aerobic exercise training on hemostatic factors
after coronary artery surgery. Br Heart J. 1992;68:181-186.
60. Ernst E, Schmid M. Regular aerobic exercise lowers fibrinogen levels: results of a pilot study. Arch Phys Med Rehabil. 1993;3:196-198.
61. Green F, Humphries S. Control of plasma fibrinogen levels. Ballieres Clin Haematol. 1989;2:945-959. [Medline] [Order article via Infotrieve]
62.
Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van de
Loo JCW. Hemostatic factors and the risk of myocardial
infarction or sudden death in patients with angina pectoris.
N Engl J Med. 1995;332:635-641.
63. Haines AP, Howarth D, North WRS, Goldenberg E, Stirling Y, Meade TW, Raftery EB, Craig MWM. Hemostatic variables and outcome of acute myocardial infarction. Thromb Haemost. 1983;50:800-803. [Medline] [Order article via Infotrieve]
64.
Ernst E, Resch KL. Fibrinogen as a
cardiovascular risk factor: a meta-analysis
and review of the literature. Ann Intern Med. 1993;118:956-963.
65.
Thompson PD, Cullinane EM, Sady SP, Flynn MM, Bernier
DMN, Kantor MA, Sartitelli AL, Herbert PN. Modest changes in
high-density lipoprotein concentration and metabolism
with prolonged exercise training.
Circulation. 1988;78:25-34.
66.
Stratton JR, Levy WC, Cerqueira MD, Schwartz RS, Abrass
IB. Cardiovascular responses to exercise: effect
of aging and exercise training in healthy men.
Circulation. 1994;89:1648-1655.
67. Behague I, Poirier O, Nicaud V, Evans A, Arveiller D, Luc G, Cambou J-P, Scarabin P-Y, Bara L, Green F, Cambien F. Association between fibrinogen gene polymorphisms, plasma fibrinogen, and coronary heart disease: the ECTIM study. Circulation. 1995. In press.
68. Humphries SE, Green FR, Henney AM, Talmud PJ. DNA polymorphisms: the variability gene concept and the risk of coronary heart disease. In: Bearn AG, ed. Genetics of Coronary Heart Disease. Oslo, Norway: Institute of Medical Genetics, University of Oslo; 1992:123-142.
69. Thomas A, Lamlum H, Humphries S, Green F. Linkage disequilibrium across the fibrinogen locus as shown by five genetic polymorphisms, G/A-455 (Hae III), C/T-148 (HindIII/Alu I), T/G+1689 (Ava II), and Bcl1 (beta-fibrinogen) and TaqI (alpha-fibrinogen), and their detection by PCR. Hum Mutat. 1994;3:79-81. [Medline] [Order article via Infotrieve]
70. Letcher RL, Chien S, Pickering TG, Sealey JE, Laragh JH. Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects: role of fibrinogen concentration. Am J Med. 1981;70:1195-1202. [Medline] [Order article via Infotrieve]
71. Ernst E, Matrai A, Scholzl C, Magyarosy I. Dose-effect relationship between smoking and blood rheology. Br J Haematol. 1987;65:485-487. [Medline] [Order article via Infotrieve]
72. Powell JT, Sian M, Wiseman S, Grennhalgh RM. Fibrinogen and carboxyhaemoglobin in peripheral arterial disease. Lancet. 1988;1:121. Letter.
73. Streiff M, Bell WR. Exercise and hemostasis in humans. Semin Hematol. 1994;31:155-165. [Medline] [Order article via Infotrieve]
74. Stout RW, Crawford V. Seasonal variations in fibrinogen concentrations among elderly people. Lancet. 1991;338:9-13.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
E. S. Ganotakis, I. F. Gazi, J. A. Papadakis, I. A. Jagroop, D. R. Nair, and D. P. Mikhailidis The Relationship Between Circulating Fibrinogen and Lipoprotein (a) Levels in Patients With Primary Dyslipidemia Clinical and Applied Thrombosis/Hemostasis, January 1, 2007; 13(1): 35 - 42. [Abstract] [PDF] |
||||
![]() |
M. Verschuur, M. de Jong, L. Felida, M. P. M. de Maat, and H. L. Vos A Hepatocyte Nuclear Factor-3 Site in the Fibrinogen {beta} Promoter Is Important for Interleukin 6-induced Expression, and Its Activity Is Influenced by the Adjacent -148C/T Polymorphism J. Biol. Chem., April 29, 2005; 280(17): 16763 - 16771. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Scott, R. A.S. Ariens, and P. J. Grant Genetic and Environmental Determinants of Fibrin Structure and Function: Relevance to Clinical Disease Arterioscler Thromb Vasc Biol, September 1, 2004; 24(9): 1558 - 1566. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. McDermott, P. Greenland, J. M Guralnik, L. Ferrucci, D. Green, K. Liu, M. H Criqui, J. R Schneider, C. Chan, P. Ridker, et al. Inflammatory markers, D-dimer, pro-thrombotic factors, and physical activity levels in patients with peripheral arterial disease Vascular Medicine, May 1, 2004; 9(2): 103 - 105. [Abstract] [PDF] |
||||
![]() |
D.J. Brull, N. Serrano, F. Zito, L. Jones, H.E. Montgomery, A. Rumley, P. Sharma, G.D.O. Lowe, M.J. World, S.E. Humphries, et al. Human CRP Gene Polymorphism Influences CRP Levels: Implications for the Prediction and Pathogenesis of Coronary Heart Disease Arterioscler Thromb Vasc Biol, November 1, 2003; 23(11): 2063 - 2069. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Lee and G. Y. H. Lip Effects of Lifestyle on Hemostasis, Fibrinolysis, and Platelet Reactivity: A Systematic Review Arch Intern Med, October 27, 2003; 163(19): 2368 - 2392. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Isasi, R. J. Deckelbaum, R. P. Tracy, T. J. Starc, L. Berglund, and S. Shea Physical Fitness and C-Reactive Protein Level in Children and Young Adults: The Columbia University BioMarkers Study Pediatrics, February 1, 2003; 111(2): 332 - 338. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Simopoulos Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases J. Am. Coll. Nutr., December 1, 2002; 21(6): 495 - 505. [Abstract] [Full Text] [PDF] |
||||
![]() |
D J Byrne, I A Jagroop, H E Montgomery, M Thomas, D P Mikhailidis, N G Milton, and A F Winder Lipoprotein (a) does not participate in the early acute phase response to training or extreme physical activity and is unlikely to enhance any associated immediate cardiovascular risk J. Clin. Pathol., April 1, 2002; 55(4): 280 - 285. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Iacoviello, M. Vischetti, F. Zito, and M. Benedetta Donati Genes Encoding Fibrinogen and Cardiovascular Risk Hypertension, November 1, 2001; 38(5): 1199 - 1203. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.J. Brull, H.E. Montgomery, J. Sanders, S. Dhamrait, L. Luong, A. Rumley, G.D.O. Lowe, and S.E. Humphries Interleukin-6 Gene -174G>C and -572G>C Promoter Polymorphisms Are Strong Predictors of Plasma Interleukin-6 Levels After Coronary Artery Bypass Surgery Arterioscler Thromb Vasc Biol, September 1, 2001; 21(9): 1458 - 1463. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Woods, D.J. Brull, S.E. Humphries, and H.E. Montgomery Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6 Eur. Heart J., October 1, 2000; 21(19): 1574 - 1583. [PDF] |
||||
![]() |
C. R. Isasi, T. J. Starc, R. P. Tracy, R. Deckelbaum, L. Berglund, and S. Shea Inverse Association of Physical Fitness with Plasma Fibrinogen Level in Children The Columbia University BioMarkers Study Am. J. Epidemiol., August 1, 2000; 152(3): 212 - 218. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. T. Brown and G. M. Fuller Detection of a Complex That Associates With the Bbeta Fibrinogen G-455-A Polymorphism Blood, November 1, 1998; 92(9): 3286 - 3293. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Pankow, A. R. Folsom, M. A. Province, D. C. Rao, R. R. Williams, J. Eckfeldt, and T. A. Sellers Segregation Analysis of Plasminogen Activator Inhibitor-1 and Fibrinogen Levels in the NHLBI Family Heart Study Arterioscler Thromb Vasc Biol, October 1, 1998; 18(10): 1559 - 1567. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Schmidt, R. Schmidt, K. Niederkorn, S. Horner, P. Becsagh, B. Reinhart, M. Schumacher, V. Weinrauch, and G. M. Kostner ß-Fibrinogen Gene Polymorphism (C148->T) Is Associated With Carotid Atherosclerosis : Results of the Austrian Stroke Prevention Study Arterioscler Thromb Vasc Biol, March 1, 1998; 18(3): 487 - 492. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. M. de Maat, J. J. P. Kastelein, J. W. Jukema, A. H. Zwinderman, H. Jansen, B. Groenemeier, A. V. G. Bruschke, and C. Kluft -455G/A Polymorphism of the ß-Fibrinogen Gene is Associated With the Progression of Coronary Atherosclerosis in Symptomatic Men : Proposed Role for an Acute-Phase Reaction Pattern of Fibrinogen Arterioscler Thromb Vasc Biol, February 1, 1998; 18(2): 265 - 271. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |